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Abstract
A balanced Robertsonian translocation results from fusion of two acrocentric chromosomes. 
Carriers are phenotypically normal, and are often diagnosed because of recurrent 
miscarriages, infertility or aneuploid offspring. Mortality and site-specific cancer risks in 
carriers have not been prospectively investigated. We followed 1987 carriers diagnosed in 
Great Britain for deaths and cancer risk, over an average of 24.1 years. Standardised mortality 
(SMR) and incidence (SIR) ratios were calculated comparing the number of observed events 
against population rates. Overall mortality was raised for carriers diagnosed aged <15 
(SMR=2.00, 95% confidence interval (CI): 1.09, 3.35), not raised for those diagnosed aged 
15-44 (SMR=1.06, 95% CI: 0.86-1.28) and reduced for those diagnosed aged 45-84 
(SMR=0.81, 95% CI: 0.68, 0.95). Cancer incidence was increased for non-Hodgkin 
lymphoma (SIR=1.90, 95% CI: 1.01, 3.24) and childhood leukaemia (SIR=14.5, 95% CI: 
1.75, 52.2), the latter particularly in rob(15;21) carriers (SIR=447.8, 95% CI: 11.3, 2495). 
Rob(13;14) carriers had a raised breast cancer risk (SIR=1.58, 95% CI: 1.12, 2.15). Mortality 
risks relative to the population in diagnosed carriers depend on age at cytogenetic diagnosis, 
possibly reflecting age-specific cytogenetic referral reasons. Carriers might be at greater risk 
of childhood leukaemia and non-Hodgkin lymphoma and those diagnosed with rob(13;14) of 
breast cancer. 
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Introduction
A balanced Robertsonian translocation involves fusion of two acrocentric chromosomes 
(chromosomes 13, 14, 15, 21, 22) with subsequent loss of the short arms. They have been 
found to form predominantly during female meiosis (1, 2). Individuals are phenotypically 
normal but are at increased risk of miscarriages, infertility and aneuploid offspring because of 
production of unbalanced gametes. Depending on which chromosomes are involved, carriers 
are at increased risk of offspring with trisomy 21 (Down syndrome) or trisomy 13 (Patau 
syndrome) (3, 4).
Balanced Robertsonian translocations represent the most common chromosomal 
rearrangements in humans. Newborn surveys estimated they occur in 1 in 1000 individuals (5-
8) with higher estimates (1 in 800) obtained from surveys of children referred for 
neurodevelopmental disease and congenital abnormalities (9). Translocations are 
disproportionally common between chromosomes 13 and 14 (rob(13;14)) and 14 and 21 
(rob(14;21)), with other combinations being rare (10, 11). Carriers of these translocations 
have 45 chromosomes, but the resulting loss of the short arms is presumed inconsequential 
because the short arms mainly contain repetitive ribosomal DNA (12, 13). However, mortality 
and site-specific cancer incidence have not been systematically investigated in carriers. 
A predisposition to haematological disorders in carriers of balanced Robertsonian 
translocations has been suggested (14), but evidence for this, and for pre-malignant conditions 
is, however, derived from case reports (14-19). Recently, carriers of rob(15;21) have been 
estimated to be at greatly increased risk of a rare form of acute lymphoblastic leukaemia 
(ALL) with intrachromosomal amplification (iAMP) of chromosome 21 (20). This was based 
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on the finding that constitutional rob(15;21) in iAMP-ALL patients was more common than 
might be expected based on newborn surveys. Risk of leukaemia has, however, not been 
prospectively investigated in Robertsonian translocation carriers overall or by subtype.
To assess risks in individuals with balanced Robertsonian translocations, one needs a cohort 
design, in which large numbers of patients are followed over a long period of time for 
mortality and cancer risk. We therefore investigated long-term risk of mortality and cancer in 
a cohort of patients diagnosed as carriers at cytogenetic centres in Great Britain. 
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Methods
Information on patients diagnosed with balanced Robertsonian translocations was obtained 
from all cytogenetic centres in Great Britain (n=27), except one small centre. Records were 
collected as far back in time as records had been maintained at each centre (in most centres 
from the 1960s or 1970s). The last year that records were abstracted ranged between 1994 and 
2006, depending on when data extraction was conducted at the centre, mostly in the late 
1990s. Prenatal records were not retrieved.
 
Patient information was matched to the National Health Service Central Register (NHSCR) 
for England and Wales and for Scotland. These registers hold information on deaths, 
emigrations and other exits from the NHS for everyone who is registered with a general 
practitioner, and are effectively population registers of these countries. Individuals who could 
be uniquely identified (‘flagged’) on the NHSCR formed the cohort and were followed-up for 
cancer incidence, death, and loss to follow-up such as through emigration. The underlying 
cause of death, from death certificates, was coded to the revision of the International 
Statistical Classification of Diseases and Related Health Problems (ICD) in use at the time of 
death, and was subsequently bridge-coded to the ninth revision of the classification (21) to 
give the categories shown in the Results. Patients were excluded if they were known to have 
been cytogenetically examined as a consequence of a cancer diagnosis. Permission for this 
study was obtained from appropriate ethics committees in the United Kingdom (UK) and the 
national personal information advisory group.
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Statistical methods
For each cohort member, we calculated person-years at risk of death by sex, 5-year age group, 
calendar year and country (England & Wales combined vs. Scotland). Follow-up started at the 
date of cytogenetic diagnosis and ended on 31 December 2016 or the eighty-fifth birthday, 
date of death or other loss to follow-up, whichever was earliest.  Follow-up was censored at 
age 85 because at older ages the certified cause of death is often inaccurate and national rates 
are not available for 5-year age group. Expected cause-specific mortality in the cohort was 
calculated by multiplying the sex-, age-, calendar year-, and country-specific person-years at 
risk in the cohort by the corresponding national mortality rates. Standardised mortality ratios 
(SMRs) were derived as the ratio of observed to expected deaths, and their 95% confidence 
intervals (CIs) calculated using exact methods (22). We calculated absolute excess rates by 
subtracting the expected from the observed numbers of deaths, dividing by person-years at 
risk and multiplying by 100,000. Analyses were conducted with STATA 14.2 (23). All 
significance tests were two-sided. 
Analyses of cancer incidence were conducted similarly, except that follow-up started on 1 
January 1971 (the date from which national cancer registrations became available) or from the 
date of the cytogenetic test, whichever was later and follow-up ended on 31 December 2015,  
the patient’s 85th birthday, date of death or date of other loss to follow-up, whichever was 
earliest. Standardised incidence ratios (SIRs) were obtained based on expected numbers from 
national cancer incidence rates. Analyses of all malignancies combined included only 
neoplasms classified as malignant according to the International Statistical Classification of 
Diseases and Related Health Problems (21), and excluded non-melanoma skin cancer because 
it is under-ascertained by the cancer registries (24). Likewise, analyses by cancer site included 
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only those coded to malignant, with the exception of central nervous system tumours for 
which non-malignant tumours were also included.
SMRs and SIRs were calculated for the entire cohort, by sex, by most common type of 
specific translocations, and by age at and calendar period of cytogenetic diagnosis and 
attained age. In order to investigate the possibility that mortality or cancer incidence might 
have been biased because some subjects were cytogenetically tested as a consequence of a 
prior illness, analyses were repeated after excluding from follow-up the first 36 months after 
cytogenetic diagnosis, because effects of such bias, if present, would be expected to ‘wear off’ 
over time.
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Results
We ascertained 2590 patients with balanced Robertsonian translocations. Among these, for 
574 subjects insufficient identifying information was available for flagging at NHSCR. A 
further 12 subjects were excluded because they could not be followed up, and 17 subjects 
because they were cytogenetically tested as a consequence of a diagnosis of cancer. A total of 
1,987 subjects were therefore included in the cohort. 
A preponderance of the cohort overall were female (59.4%) (Table 1). The greatest female 
excess was among those diagnosed aged 15-44 (63.0%), whereas there was no appreciable 
female excess among those diagnosed in childhood (50.4% female) (not in table). Nearly one 
third of carriers (30.8%) were diagnosed at ages 25-34 years and the majority of carriers 
(62.4%) were diagnosed during 1990-2006. Robertsonian translocations most frequently 
involved chromosomes 13 and 14 (62.8%) or chromosomes 14 and 21 (19.6%), with other 
combinations being much less common. 
During mortality follow-up, 257 subjects died, 86 subjects exited the study when they reached 
age 85, 92 exited because of emigration or other reasons, and 1,552 were followed until the 
end of the study. The average follow-up was 24.1 (ranging from 0.01 to 55.0) years per 
subject.
Overall mortality in the cohort relative to the general population was non-significantly 
reduced (SMR=0.92, 95% CI: 0.81, 1.04), corresponding to 44.5 fewer cases per 100,000 
population (Table 2). Mortality ratios were somewhat lower for males (SMR=0.87, 95% CI: 
0.73, 1.03) than for females (SMR=0.98, 95% CI: 0.82, 1.17) and lower for subjects 
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diagnosed since 1980 compared with earlier (not shown). Mortality from congenital 
anomalies was significantly raised (SMR=4.72, 95% CI: 1.53, 11.0), with the five deaths 
being from heterogeneous anomalies and four occurring within 3 years of cytogenetic 
diagnosis.
Analyses of SMRs by age at cytogenetic diagnosis showed raised mortality in patients 
diagnosed in childhood (SMR=2.00, 95% CI: 1.09, 3.35, age 0-14 years) (Table 3). Cause-
specific mortality was significantly raised for nervous system disease (SMR=11.9, 95% CI: 
3.25, 30.5) and congenital anomalies (SMR=14.6, 95% CI: 4.74, 34.1). When we repeated the 
analyses excluding follow-up <36 months after cytogenetic diagnosis, the SMRs for mortality 
from all causes (SMR=0.71, 95% CI: 0.19, 1.83) and from congenital abnormalities or 
nervous system disease were no longer significantly raised (not shown). 
Mortality among subjects diagnosed at ages 15-44 was similar to that in the general 
population (SMR=1.06, 95% CI: 0.86, 1.28). In those diagnosed at age 45, mortality was 
significantly reduced (SMR=0.81, 95% CI: 0.68, 0.95) (Table 3), to a similar extent in males 
and females (SMR 0.82 and 0.80, respectively, not in table).  Risk was decreased in particular 
for circulatory disease (SMR=0.76, 95% CI: 0.58, 0.99), including ischaemic heart disease 
(SMR=0.57, 95% CI: 0.36, 0.85) and cardiac disease (SMR=0.59, 95% CI: 0.35, 0.94) (not in 
table). Analyses of mortality from cancer showed a decreased risk for colorectal cancer in 
carriers overall, but no association for other cancer sites (Table 4).
Mortality for the two main types of translocations, rob(13;21) and rob(14;21), separately were 
not materially different from the overall results except for  raised mortality of diseases of the 
nervous system in rob(14;21) carriers (Table S1) and that all deaths from myeloma occurred 
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in  rob(13;14) carriers (SMR=5.02, 95% CI: 1.37, 12.9 for overall follow-up and SMR=2.44, 
95% CI: 0.50, 7.14 for 36 months of follow-up) (not in table). 
The analyses of cancer incidence included 1981 subjects (Table 4). During follow-up, 202 
malignant neoplasms and four non-malignant nervous system tumours occurred (Table 4). 
Risk was raised for non-Hodgkin lymphoma (SIR=1.90, 95% CI: 1.01, 3.24). The cases 
occurred 5-31 years after cytogenetic diagnosis and the SIR remained significant after 
excluding the first 36 months of follow-up.  Twelve of the 13 cases involved chromosome 14 
including 9 with rob(13;14) (SIR=2.12, 95% CI: 0.97, 4.03 for rob(13;14) carriers) (table S2). 
Risks for other types of haematological cancer in the patients overall were not raised (Table 
4). 
Risk of breast cancer incidence not significantly raised overall (SIR=1.27, 95% CI: 0.94, 
1.67) (Table 4) and by age at cytogenetic diagnosis (SIR=0 for age <15, 1.26 for age 15-44 
and 1.39 for age 45-84 years) (not in table). Risk was significantly raised, however, in 
rob(13;14) (SIR=1.58, 95% CI: 1.12, 2.15), but not rob(14;21) (SIR=0.73, 95% CI: 0.27, 
1.59) carriers (Table S2). After excluding follow-up in the first 36 months after cytogenetic 
diagnosis, the SIR for breast cancer in rob(13;14) carriers remained significantly raised (not 
shown). Risk of colorectal cancer was borderline significantly reduced in rob(13;14) carriers 
(SIR=0.45, 95% CI: 0.17, 0.99) (Table S2). 
In analyses of haematological disorders by attained age, carriers were at increased risk of 
leukaemia diagnosed in childhood (age 0-14 years) (SIR=14.5, 95% CI: 1.75, 52.2) (Table 5). 
The 2 cases were diagnosed with acute lymphoblastic leukaemia 2 and 10 years after 
cytogenetic diagnosis, respectively. One patient had a constitutional translocation rob(15;21) 
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(SIR=447.8, 95% CI: 11.3, 2495 for leukaemia of any type at ages 0-14 years among 
rob(15;21) carriers) and the other rob(13;14) (SIR=11.74, 95% CI: 0.30, 65.4 among 
rob(13;14) carriers) (not in table). Among the 13 cases with non-Hodgkin lymphoma, 11 were 
diagnosed at age 45 and over (SIR=1.89, 95% CI: 0.95, 3.38). In analyses by age at 
cytogenetic diagnosis, SIRs were not significantly raised for haematological disorders (Table 
S3). 
We ascertained reasons for referral for cytogenetic testing among 250 patients postnatally 
diagnosed at the Wessex Regional Genetics Laboratory. Among subjects cytogenetically 
tested under age 20 years, the main reasons were a family history of Robertsonian 
translocation or other abnormality (48%), or abnormalities and developmental delay (34%). 
Among those diagnosed at ages 20-44, the main reasons were offspring with a Robertsonian 
translocation or Down’s (40%), other family history of such abnormalities (28%) or fertility-
related problems (24%). Subjects diagnosed at older ages were predominantly referred 
because they were parents (62%) or other relatives (24%) of individuals with cytogenetic 
abnormalities.
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Discussion
Our study is the first to report on mortality and site-specific cancer risks in carriers of 
balanced Robertsonian translocations. It has the strength that it was prospective, based on 
carriers from a large population over a long period of follow-up, and that mortality and cancer 
outcome data were collected in an unbiased manner and could be compared against 
population rates. Overall mortality rates were similar to those expected based on general 
population rates, but we observed differences in age-specific mortality. Cancer risks overall 
were also similar, consistent with the only other, much smaller, cohort study of 730 carriers 
from Denmark, which only reported on overall cancer incidence (25). Site-specific analyses in 
our study showed, however, significant increased risks of non-Hodgkin lymphoma and 
childhood leukaemia in carriers overall, and of breast cancer in rob(13;14) carriers. 
The years for which we extracted records varied by cytogenetic centre depending on the years 
the centre was operational, availability of historical records and the calendar period of 
extraction. We estimate that we extracted information for 55% of all individuals diagnosed in 
Great Britain during 1962-2006. This is unlikely to lead to bias, however, as the availability 
of records for operational reasons is expected to be unrelated to later cancer incidence and 
mortality. Most carriers are not detected unless they get referred for cytogenetic testing for 
experiencing problems with reproductive problems or abnormalities in offspring. We 
estimate, for the years we have the greatest numbers of carriers (1988-1998), that 20% of 
carriers are eventually diagnosed, based on a newborn prevalence of 1 in 1000 and the 
number of births in Great Britain during this period. Our study is therefore of patients with 
Robertsonian translocations who are diagnosed, but from a clinical and counselling 
perspective this is the group of cases of relevance. However, the selective forces that lead to 
diagnosis are then important in the interpretation of our results. Information from the Wessex 
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centre showed that in subjects diagnosed in childhood, referral for cytogenetic testing and 
hence diagnosis of a balanced Robertsonian translocation was often a consequence of existing 
morbidity. The effect of such referral bias would be expected to be greatest in the early years 
after cytogenetic diagnosis and diminish with time. The observation that SMRs for patients 
diagnosed with balanced Robertsonian translocation in childhood were not raised after 
excluding the first 36 months of follow-up suggests that the raised SMRs for these patients 
were due to such bias.
The majority of carriers were diagnosed at ages 15-44, with their referral reasons related to 
infertility or having offspring with cytogenetic abnormalities. We observed that mortality in 
this group was comparable to that of the general population but that mortality was reduced 
among carriers diagnosed at ages 45 and over, in particular from circulatory disease. The age-
specificity of this finding suggests a role of referral bias rather than a genetic effect. Data on 
referral reasons in Wessex suggest that older subjects are usually referred for testing because 
of cytogenetic abnormality in their own children or other relatives. Reduced mortality in 
subjects diagnosed later in life might therefore be due to a selective referral of subjects who 
are physically well enough to have had children of their own and willing and well enough to 
be cytogenetically tested (26). Additionally, although the national health system of Great 
Britain provides access to cytogenetic testing free-of-charge to those who are referred, it is 
possible that carriers who are diagnosed at later ages have a higher socioeconomic status than 
the general population, which is associated with  lower overall and cardiovascular mortality 
(27).
The reason for referral for cytogenetic testing, and hence degree of referral bias, may also 
depend on karyotype or sex (4, 28). We observed a strong preponderance of female carriers 
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overall, which was most pronounced at female reproductive ages, whereas there was no 
female excess among carriers diagnosed in childhood. The reason for the disparity in numbers 
by sex is therefore likely to be related to reproduction-related reasons for referral. We found, 
however, no evidence that mortality rates were different between rob(13;14) and rob(14;21), 
or between males and females.
Rob(13;14) and rob(14;21) constituted 82.4% of all translocations in our cohort, in range with 
previous estimates of 74-85% (10, 11). The preferential formation of these karyotypes is 
thought to be consequence of recombination between inverted homologous sequences shared 
by these chromosomes (11, 29). Breakpoints in these translocations have been reported to be  
very consistent and localized to specific regions in the proximal acrocentric short arms, 
preferentially in satellite III DNA, resulting in a dicentric chromosome (12, 29). 
Translocations involving other combinations of chromosomes are much less common, in 
particular between homologous chromosomes. For these translocations, breakpoints are 
variable and it is thought that they might be formed through a different mechanism (2, 11-13).
The risk of non-Hodgkin lymphoma in balanced Robertsonian translocation carriers  does not 
appear to have been investigated before and while acquired reciprocal translocations are 
common in lymphoma and leukaemia (30), the mechanism by which carriers might be 
predisposed is not clear. Pathak proposed in 1986 that constitutional translocations, 
specifically rob(13;14), may predispose to T- or B-cell malignancies, depending on the 
breakpoint in chromosome 14 (14). This author postulated that predisposition to T-cell 
malignancy might result due to a break in 14q11 (T-cell alpha-receptor locus), whereas 
predisposition to a B-cell malignancy, which includes most non-Hodgkin lymphomas, could 
be due to a tandem t(13;14) translocation with a breakpoint at 14q32. It is not clear, however, 
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how the breakpoints involved in balanced Robertsonian translocations could affect 
predisposition to malignancy. Welborn reported that acquired Robertsonian translocations 
occur in haematological malignancies in 1 in 300-400 patients and that 60% of these 
translocations are isochromosomes 13, 14 or 21  (31). 
Li et al (2014) recently estimated that constitutional rob(15;21) carriers are at >2700-fold 
increased risk of iAMP21-ALL, an rare form of ALL involving amplification of chromosome 
21, and proposed a novel mechanism for cancer predisposition (20). However, their risk 
estimate was based on the number of constitutional rob(15;21) carriers in a series of iAMP-
ALL cases and the estimated frequency of rob(15;21) from newborn surveys. Our study is the 
first prospective investigation of this hypothesis. Rob(15;21) is very rare, with our cohort 
including only 35 carriers, including five karyotyped aged <15 years. One carrier developed 
ALL aged <15 years, corresponding to a significant ~450-fold increased risk, albeit with a 
wide confidence interval. We estimate that, if this association were causal, the cumulative risk 
of leukaemia (of all subtypes) to the age of 15 in t(15;21) carriers is 28% (between 0.8-83% 
based on the confidence interval of the SIR). Among the 500-600 new childhood cases of 
leukaemia in Great Britain annually, about 4 might be t(15;21) carriers, but our estimates are 
uncertain because they are based on one case only. We have no information on tumour profile 
and therefore do not know whether our case had iAMP-ALL, given that IAMP constitutes 
only 2.1% of all ALL cases (32), but iAMP-ALL patients have been reported to be somewhat 
older than ALL patients overall (20), consistent with our patient. Our study therefore supports 
the hypothesis of increased susceptibility of rob(15;21) carriers to acute lymphoblastic 
leukaemia.  
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There are no previous data on breast cancer risk in balanced Robertsonian translocation 
carriers. The observed significantly raised risk in rob(13;14) carriers could be a result of 
chance or because nulliparity and delayed child birth are risk factors for breast cancer. 
However, given the age-specific differences in referral reasons, the similar SIRs for women 
cytogenetically diagnosed aged 15-44 and 45-84 argues somewhat against the latter. Raised 
breast cancer rates could also arise if our cohort is of higher socioeconomic profile than the 
general population overall, breast cancer rates being greater in higher socioeconomic strata 
(33). However, alternatively, it might be that the finding reflects a previously undiscovered 
genetic cause. 
We also observed decreased mortality from colorectal cancer in carriers overall and decreased 
incidence of this cancer in rob(13;14) carriers, but not in carriers overall. Mortality, but not 
incidence, of myeloma in rob(13;14) carrie s was raised. Given that the relative risks were not 
consistent between analyses, we regard these results as inconclusive and the findings would 
need re-examination in other studies. 
In conclusion, our study suggests that subjects diagnosed with balanced Robertsonian 
translocations may be at increased risk of childhood leukaemia and non-Hodgkin lymphoma 
and those diagnosed with rob(13;14) might have a raised breast cancer risk, but that their 
mortality is not raised compared with that in the general population. These findings might be 
related to genetic factors as well as to factors associated with reasons for referral for 
cytogenetic testing. 
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Table 1: Characteristics of the cohort of subjects cytogenetically diagnosed with balanced 
Robertsonian translocations during 1962-2006 (varying by centre) in Great Britain
Characteristic No. % Person-years
Sex
Male 807 40.6 19,355
Female 1180 59.4 28,543
Age at diagnosis (years)
0-4 240 12.1 6,306
5-14 110 5.5 3,283
15-24 318 16.0 8,488
25-34 612 30.8 15,033
35-44 333 16.8 7,831
45-64 289 14.5 6038
65-84 85 4.3 918
Year of diagnosis
1962-1969 121 6.1 4,064
1970-1979 181 9.1 6,351
1980-1989 445 22.4 12,315
1990-2006 1,240 62.4 25,169
Year of birth
<1950 544 27.4 12,926
1950-1969 935 47.1 23,079
1970-1989 378 19.0 9,302
1990-2005 130 6.5 2,592
Chromosomes involved
13;13 2 0.1 58
13;14 1,248 62.8 29,967
13;15 55 2.8 1,225
13;21 20 1.0 490
13;22 20 1.0 483
14;14 5 0.3 100
14;15 52 2.6 1,129
14;21 390 19.6 9,438
14;22 57 2.9 1,303
15;15 2 0.1 35
15;21 35 1.8 816
15;22 35 1.8 942
21;21 6 0.3 179
21;22 38 1.9 1,101
22;22 10 0.5 277
Othera 12 0.6 356
Total 1,987 100.0 47,899
a) Including 7 Robertsonian translocations between two D group chromosomes, 4 between a D and G 
group chromosome, and 1 patient mosaic for two different Robertsonian translocations
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Table 2: Cause-specific mortality in 1,987 subjects with balanced Robertsonian 
translocations cytogenetically diagnosed during 1962-2006 in Great Britain
ICD-9
Code Cause
No. of 
deaths
SMR 95% CI AER
140-208 All malignant neoplasms 81 0.88 0.70, 1.10 -22.5
240-279 Endocrine, nutritional, metabolic, 
immunity
3 0.71 0.15, 2.07 -2.6
290-319 Mental disorders 4 0.70 0.19, 1.80 -3.5
320-389 Diseases of the nervous system 12 1.57 0.81, 2.75 9.1
390-459 Diseases of the circulatory system 83 0.86 0.69, 1.07 -28.4
410-414 Ischaemic heart disease 42 0.77 0.55, 1.04 -26.4
410 Acute myocardial infarction 29 0.91 0.61, 1.30 -6.3
420-429 Other heart disease 8 1.01 0.44, 1.99 0.20
430-437 Cerebrovascular disease 20 0.93 0.57, 1.43 -3.2
460-519 Diseases of the espiratory system 30 1.01 0.68, 1.44 0.70
480-486 Pneumonia 11 1.11 0.55, 1.98 2.2
490-494, 496 Chronic lower respiratory disease 10 0.67 0.32, 1.24 -10.2
520-579 Diseases of the digestive system 13 0.90 0.48, 1.53 -3.1
570-572, 573.0, 
573.3-573.9
Liver disease 7 1.05 0.42, 2.17 0.71
580-629 Diseases of the genitourinary system 3 0.89 0.18, 2.59 -0.80
710-739 Musculoskeletal system and 
connective tissue
1 0.63 0.02, 3.48 -1.30
740-759 Congenital anomalies 5 4.72a 1.53, 11.0 8.2
800-999 Accidents and violence 14 0.96 0.52, 1.60 -1.33
001-999 All causesb 257 0.92 0.81, 1.04 -44.5
Abbreviations: AER, absolute excess rate, number of excess deaths per 100,000 population per annum; CI, 
confidence interval; ICD, International Statistical Classification of Diseases, 9th revision (21); SMR, 
standardised mortality ratio
a) two-sided P-value based on exact method p<0.01  
b) Includes 8 deaths from causes not listed individually in the table (4 unknown, 2 senility, 1 infarction of spleen, 
1 myelodysplastic syndrome) 
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Table 3:  Cause-specific mortality in 1,987 subjects cytogenetically diagnosed with balanced Robertsonian translocations during 1962-2006 in 
Great Britain, by age at cytogenetic diagnosis
Age at cytogenetic diagnosis (years)
0-14 15-44 45-84
ICD-9 code Cause No. SMR 95% CI No. SMR 95% CI No. SMR 95% CI
140-208 All malignant neoplasms 0 0.00 0.0, 3.08 34 0.96 0.67, 1.34 47 0.85 0.63, 1.13
240-279 Endocrine, nutritional, metabolic, immunity 0 0.0 0.0, 22.5 1 0.63 0.02, 3.52 2 0.80 0.10, 2.90
290-319 Mental disorders 0 0.0 0.0, 13.5 2 1.06 0.13, 3.82 2 0.57 0.07, 2.05
320-389 Diseases of the nervous system 4 11.9a 3.25, 30.5 4 1.31 0.36, 3.34 4 0.95 0.26, 2.43
390-459 Diseases of the circulatory system 0 0.0 0.0, 5.03 28 1.18 0.78, 1.70 55 0.76b 0.58, 0.99
460-519 Diseases of the respiratory system 1 2.83 0.07, 15.8 9 1.25 0.57, 2.37 20 0.91 0.56, 1.40
520-579 Diseases of the digestive system 1 2.50 0.06, 13.9 6 0.84 0.31, 1.83 6 0.86 0.32, 1.88
580-629 Diseases of the genitourinary system 0 0.0 0.0, 103.9 1 1.19 0.03, 6.64 2 0.80 0.10, 2.88
710-739 Musculoskeletal system and connective tissue 0 0.0 0.0, 141.0 1 1.97 0.05, 11.0 0 0.0 0.0, 3.46
740-759 Congenital anomalies 5 14.6a 4.74, 34.1 0 0.0 0.0, 6.93 0 0.0 0.0, 19.9
800-999 Accidents and violence 1 0.48 0.01, 2.65 10 1.11 0.53, 2.05 3 0.84 0.17, 2.47
001-999 All causesc 14 2.00b 1.09, 3.35 99 1.06 0.86, 1.28 144 0.81b 0.68, 0.95
Abbreviations: CI, confidence interval; ICD, International Statistical Classification of Diseases, 9th revision (21); SMR, standardised mortality ratio
a) two-sided P-value based on exact method p<0.001
b) two-sided P-value based on exact method p<0.05  
c) Includes 8 deaths from causes not listed individually in the table (4 unknown, 2 senility, 1 infarction of spleen, 1 myelodysplastic syndrome)
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Table 4:  Cancer incidence and mortality in subjects cytogenetically diagnosed with balanced 
Robertsonian translocations during 1962-2006 in Great Britain
Incidence
(carriers n=1981)
Mortality
(carriers n=1987)
ICD-9 code Cancer site No. SIR  95% CI No. SMR 95% CI
140-171, 
173-208
All malignant 
neoplasmsa
202 1.05 0.91, 1.20 81 0.88 0.70, 1.10
141-149 Tongue, mouth, 
pharynx
6 1.41 0.52, 3.07 1 0.68 0.02, 3.79
150 Oesophagus 3 0.69 0.14, 2.02 5 1.24 0.40, 2.88
151 Stomach 6 1.21 0.45, 2.62 2 0.55 0.07, 1.99
153, 154 Colon and rectum 14 0.65 0.35, 1.09 3 0.33b 0.07, 0.97
155 Liver 1 0.52 0.01, 2.91 1 0.55 0.01, 3.09
157 Pancreas 4 0.92 0.25, 2.35 5 1.18 0.38, 2.75
162 Lung 23 0.88 0.56, 1.32 18 0.79 0.47, 1.26
163 Pleura 2 1.93 0.23, 6.97 0 0.0 0.0, 10.3
170 Bone 1 2.76 0.07, 15.4 0 0.0 0.0, 18.5
172 Cutaneous 
melanoma
8 1.08 0.47, 2.14 1 0.82 0.02, 4.57
174, 175 Breast 50 1.27 0.94, 1.67 13 1.42 0.76, 2.44
179,182 Corpus uteri 5 0.95 0.31, 2.21    0 0.0 0.0, 3.51
180 Cervix 2 0.55 0.07, 2.00 0 0.0 0.0, 3.18
183 Ovary 6 1.09 0.40, 2.36 1 0.32 0.01, 1.81
184.0-184.4 Vagina & vulva 2 2.20 0.27, 7.95 1 4.12 0.10, 22.9
185 Prostate 23 1.42 0.91, 2.14 6 1.53 0.56, 3.34
186 Testis 1 0.67 0.02, 3.72 0 0.0 0.0, 44.0
187.1-187.4 Penis 2 7.01 0.85, 25.3 0 0.0 0.0, 56.7
188 Bladder and urethra 5 0.85 0.28, 1.98 4 1.66 0.45, 4.26
189 Kidney and ureter 1 0.20 0.01, 1.13 1 0.49 0.01, 2.71
190 Eye 1 2.46 0.06, 13.7 0 0.0 0.0, 50.0
191, 192, 
225, 237.5, 
237.6, 237.9, 
239.6
Nervous system 
tumours, including 
benignc 
8 1.47 0.64, 2.90 3 0.95 0.20, 2.78
193 Thyroid 2 1.13 0.14, 4.06 0 0.0 0.0, 18.8
196.0-199.1 Unknown primary 
site
5 0.81 0.26, 1.88 6 0.88 0.32, 1.91
200, 202 Non-Hodgkin 
lymphoma
13 1.90b 1.01, 3.24 4 1.57 0.43, 3.24
201 Hodgkin disease 1 0.79 0.02, 4.39 1 3.68 0.09, 20.5
203 Myeloma 4 1.76 0.48, 4.48 4 3.06 0.83, 7.81
204-208 Leukaemia 6 1.39 0.51, 3.02 0 0.0 0.0, 1.61
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Abbreviations: ; CI, confidence interval; ICD, International Statistical Classification of Diseases, 9th revision 
(21); SIR, standardised incidence ratio; SMR, standardised mortality ratio
a) All malignant neoplasms except non-melanoma skin cancer. 1 death (from malignancy of ‘other’ part of 
digestive system) and 1 incident cancer (maxillary sinus) were not listed individually.
b) two-sided P-value based on exact method p<0.01
c) The 8 observed incident tumours included comprise 4 malignant cancers of the brain and 4 benign neoplasms 
of the meninges. For England and Wales, benign nervous system neoplasms were included from the year 1971, 
for Scotland from the year 2000. The three deaths for nervous system tumours were all malignant.
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Table 5: Incidence of malignancies overall and of haematological malignancies in subjects cytogenetically diagnosed with balanced 
Robertsonian translocations during 1962-2006 in Great Britain, by attained age 
Attained age (years)
0-14 15-44 45-84
ICD-9 code Cause No. SIR 95% CI No. SIR 95% CI No. SIR 95% CI
140-171, 173-208 All malignant neoplasmsa 3 6.86b 1.41, 20.1 23 1.02 0.65, 1.53 176 1.04 0.89, 1.20
200, 202 Non-Hodgkin lymphoma 1 32.1 0.81, 179 1 0.99 0.03, 5.53 11 1.89 0.94, 3.38
201 Hodgkin disease 0 0.0 0.0, 151 1 1.43 0.04, 7.96 0 0.0 0.0, 6.77
203 Myeloma 0 0.0 0.0, 30122 0 0.0 0.0, 37.6 4 1.83 0.50, 4.69
204-208 Leukaemia 2 14.5b 1.75, 52.2 0 0.0 0.0, 6.14 4 1.12 0.31, 2.86
Abbreviations: CI, confidence interval; ICD, International Statistical Classification of Diseases, 9th revision (21); SIR, standardised incidence ratio
a) All malignant neoplasms except non-melanoma skin cancer. 
b) two-sided P-value based on exact method p<0.05
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Table S1: Cause-specific mortality in subjects cytogenetically diagnosed with balanced Robertsonian translocations during 1962-2006 in Great 
Britain, for translocations involving chromosomes 13 and 14 and chromosomes 14 and 21 
Chromosomes involved 
rob(13;14) rob(14;21)
ICD-9 Cause No. SMR 95% CI AER No. SMR 95% CI AER
140-208 All malignant neoplasms 55 0.97  0.73, 1.27 -4.80 14 0.74  0.40, 1.24 -52.2
240-279 Endocrine, nutritional, metabolic, immunity 2 0.77  0.09, 2.78 -2.00 1 1.15  0.03, 6.41 1.40
290-319 Mental disorders 3 0.87  0.18, 2.55 -1.50 1 0.83  0.02, 4.60 -2.20
320-389 Diseases of the nervous system 2 0.43  0.05, 1.55 -8.90 6 3.68a  1.35, 8.01 46.3
390-459 Diseases of the circulatory system 54 0.90  0.68, 1.17 -20.3 14 0.75  0.41, 1.26 -48.9
460-519 Diseases of the respiratory system 17 0.93  0.54, 1.49 -4.10 6 0.99  0.36, 2.15 -0.70
520-579 Diseases of the digestive system 7 0.78  0.31, 1.60 -6.70 4 1.38  0.38, 3.54 11.7
580-629 Diseases of the genitourinary system 2 0.96  0.12, 3.46 -0.30 0 0.0  0.0, 5.38 -7.30
710-739 Musculoskeletal system and connective tissue 0 0.0  0.0, 3.77 -3.30 1 2.81  0.07, 15.6 6.82
740-759 Congenital anomalies 2 3.12  0.38, 11.3 4.50 1 4.79  0.12, 26.5 8.40
800-999 Accidents and violence 11 1.18  0.59, 2.11 5.60 2 0.74  0.09, 2.65 -7.70
001-999 All causesb 160 0.93  0.79, 1.09 -40.5 50 0.90  0.67, 1.18 -60.8
Abbreviations: AER, absolute excess rate,  number of excess deaths per 100,000 population per annum; CI, confidence interval;  ICD, International Statistical Classification 
of diseases, 9th revision (21);  SMR, standardised mortality ratio
a) two-sided P-value based on exact method p<0.05
b) The causes of five deaths in subjects diagnosed with rob(13;14) are not listed separately (2 not known, 1 senility, 1 myelodysplastic syndrome, 1 infarction of spleen)
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Table S2:  Cancer incidence in subjects cytogenetically diagnosed with balanced 
Robertsonian translocations during 1962-2006 in Great Britain, for translocations involving 
chromosomes 13 and 14 and chromosomes 14 and 21 
rob(13;14) rob(14;21)
ICD-9 
code
Cancer site No. SIR  95% CI No. SIR  95% CI
140-171, 
173-208
All malignant neoplasmsa 131 1.10  0.92, 1.31 39 0.98  0.70, 1.34
141-149 Tongue, mouth, pharynx 4 1.51  0.41, 3.88 1 1.22  0.03, 6.77
150 Oesophagus 2 0.76  0.09, 2.74 1 1.14  0.03, 6.34
151 Stomach 5 1.64  0.53, 3.82 1 1.01  0.03, 5.63
153, 154 Colon and rectum 6 0.45b  0.17, 0.99 6 1.34  0.49, 2.91
155 Liver 1 0.85  0.02, 4.76 0 0.0  0.00, 9.45
157 Pancreas 1 0.37  0.01, 2.08 1 1.09  0.03, 6.05
162 Lung 15 0.93  0.52, 1.54 4 0.78  0.21, 1.98
163 Pleura 1 1.62  0.04, 9.00 0 0.0  0.0, 16.9
170 Bone 1 4.43  0.11, 24.7 0 0.0  0.0, 52.3
172 Cutaneous melanoma 4 0.88  0.24, 2.24 3 1.98  0.41, 5.77
174, 175 Breast 39 1.58c  1.12, 2.15 6 0.73  0.27, 1.59
179,182 Corpus uteri 4 1.21  0.33, 3.09 0 0.0  0.0, 3.21
180 Cervix 2 0.89  0.11, 3.23 0 0.0  0.0, 4.94
183 Ovary 3 0.87  0.18, 2.54 1 0.83  0.02, 4.65
184.0-
184.4
Vagina & vulva 1 1.76  0.04, 9.80 0 0.0  0.0, 18.8
185 Prostate 14 1.47  0.80, 2.47 4 1.18  0.32, 3.02
186 Testis 0 0.0  0.0, 3.75 1 3.77  0.10, 21.0
187.1-
187.4
Penis 1 5.73  0.14, 31.9 1 18.4  0.47, 103
188 Bladder and urethra 3 0.83  0.17, 2.44 0 0.0  0.0, 3.08
189 Kidney and ureter 0 0.00  0.00, 1.23 0 0.0  0.0, 3.65
190 Eye 0 0.00  0.00, 14.7 1 12.6  0.32, 69.4
191, 192, 
225, 
237.5, 
237.6, 
237.9, 
239.6
Nervous system tumours, 
including benignb
6 1.78  0.65, 3.87 2 1.78  0.22, 6.45
193 Thyroid 0 0.0  0.0, 3.35 1 2.71  0.07, 15.1
196.0-
199.1
Unknown primary site 3 0.79  0.16, 2.31 1 0.77  0.02, 4.27
200, 202 Non-Hodgkin lymphoma 9 2.12  0.97, 4.03 3 2.10  0.43, 6.14
201 Hodgkin disease 0 0.00  0.00, 4.66 1 3.96  0.10, 22.1
203 Myeloma 4 2.87  0.78, 7.34 0 0.0  0.0, 7.60
204-208 Leukaemia 4 1.51  0.41, 3.86 1 1.12  0.03, 6.27
Abbreviations: CI, confidence interval; ICD, International Statistical Classification of Diseases, 9th revision (21); 
SIR, standardised incidence ratio
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a)All malignant neoplasms except non-melanoma skin cancer. 1 cancer (maxillary sinus) is not listed separately 
under the rob(13;14).
b) two-sided P-value based on exact method p<0.05
c) two-sided P-value based on exact method p<0.01
d) The 8 observed tumours included comprise 4 malignant cancers of the brain and 4 benign neoplasms of the 
meninges. For England and Wales, benign nervous system neoplasms were included from the year 1971 for 
Scotland, from the year 2000. 
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Table S3: Incidence of cancer overall and of haematological malignancies in subjects cytogenetically diagnosed with balanced Robertsonian 
translocations during 1962-2006 in Great Britain, by age at cytogenetic diagnosis
Age at cytogenetic diagnosis (years)
0-14 15-44 45-84
ICD-9 code Cause No. SIR 95% CI No. SIR 95% CI No. SIR 95% CI
140-171, 173-
208
All malignant neoplasmsa 5 1.07  0.35, 2.50 104 1.09  0.89, 1.32 93 1.01  0.82, 1.24
200, 202 Non-Hodgkin lymphoma 1 4.24  0.11, 23.6 7 1.93  0.78, 3.98 5 1.66  0.54, 3.88
201 Hodgkin disease 1 4.51  0.11, 25.1 0 0.0  0.0, 4.43 0 0.0  0.0, 17.2
203 Myeloma 0 0.0  0.0, 162 3 3.16  0.65, 9.23 1 0.76  0.02, 4.25
204-208 Leukaemia 2 6.99  0.85, 25.2 3 1.53  0.32, 4.47 1 0.48  0.01, 2.69
Abbreviations: CI, confidence interval; ICD, International Statistical Classification of diseases, 9th revision (21); SIR, standardised incidence ratio 
a) All malignant neoplasms except non-melanoma skin cancer
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